AbbVie presented new clinical data on its lung cancer treatments at the 2026 World Conference on Lung Cancer, highlighting ABBV-1480, telisotuzumab adizutecan (Temab-A), and ABBV-706. ABBV-1480 showed high response rates in frontline non-small cell lung cancer (NSCLC) with manageable safety, supporting Phase 3 trials. Temab-A is being studied for advanced NSCLC, including combinations with PD-1 inhibitors, while ABBV-706 demonstrated strong activity and manageable side effects in small cell lung cancer (SCLC). These developments reflect AbbVie's strategy to advance next-generation immunotherapies and targeted antibody-drug conjugates for lung cancer treatment.
Pfizer, Chevron, and AbbVie have delivered strong dividend returns in 2026 and are positioned for further growth in 2027. Pfizer aims for $35 per share driven by obesity and oncology products, Chevron targets $250 supported by Guyana projects and AI ...
Piper Sandler raised AbbVie's price target to $303, indicating a potential 13.92% upside from its current price of $265.97. This reflects positive expectations for the biopharmaceutical company's future performance. Institutional investors like J. M....
Kailera Therapeutics recently closed at $18.51, down 2.5% for the week and 28.8% since its April IPO. The clinical-stage company, with no product revenue, holds $1.17 billion in cash and has a runway into mid-2028. Its lead drug, ribupatide, is in gl...
AbbVie announced 34 recipients of its 2026 Immunology Scholarship, supporting students with chronic inflammatory diseases like psoriasis and Crohn's. The scholarship, now renewable for up to four years and worth up to $20,000 annually, helps ease fin...
RoseNose Investing Group's Income Portfolio, yielding 5.6%, reached an all-time high value for the third time in July and is up 12.11% year-to-date. The portfolio includes 15 stocks flagged as overvalued due to their proximity to 52-week highs and lo...
